



# Source details

## Anaesthesia, Pain and Intensive Care

Open Access ⓘ

Scopus coverage years: from 2009 to Present

Publisher: Pakistan Society of Anaesthesiologists

ISSN: 1607-8322

Subject area: Medicine: Anesthesiology and Pain Medicine Medicine: Critical Care and Intensive Care Medicine

Source type: Journal

CiteScore 2022

0.4 ⓘ

SJR 2022

0.140 ⓘ

SNIP 2022

0.150 ⓘ

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### Improved CiteScore methodology ⓘ

CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022. [Learn more >](#)

### CiteScore 2022 ▾

$$0.4 = \frac{175 \text{ Citations 2019 - 2022}}{449 \text{ Documents 2019 - 2022}}$$

Calculated on 05 May, 2023

### CiteScoreTracker 2023 ⓘ

$$0.4 = \frac{183 \text{ Citations to date}}{478 \text{ Documents to date}}$$

Last updated on 05 September, 2023 • Updated monthly

### CiteScore rank 2022 ⓘ

Category	Rank	Percentile
Medicine		
↳ Anesthesiology and Pain Medicine	#103/124	17th
Medicine		
↳ Critical Care and Intensive Care Medicine	#89/100	11th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)

ⓘ ×

## Claim Your Free Trial

American Journal Experts Op

## Anaesthesia, Pain and Intensive Care

### COUNTRY

Pakistan



Universities and research institutions in Pakistan



Media Ranking in Pakistan

### SUBJECT AREA AND CATEGORY

Medicine

Anesthesiology and Pain Medicine

Critical Care and Intensive Care Medicine

### PUBLISHER

Faculty of Anaesthesia, Pain and Intensive Care, AFMS

### H-INDEX

11

### PUBLICATION TYPE

Journals

### ISSN

16078322

### COVERAGE

2009-2022

### INFORMATION

[Homepage](#)

[How to publish in this journal](#)

[brigsaleem1@gmail.com](mailto:brigsaleem1@gmail.com)

## Submit Paper for Publication

International Widely Indexed Open Access  
Scholarly Academic Research Journal

Open

**Physical Education Journal**

Index Copernicus Indexed

Index Copernicus Journal. Allots DOI by CrossRef for each Article.

iosrjournals.org OPEN

SCOPE

'Anaesthesia, Pain & Intensive Care' aims to provide a medium of scientific research and the current developments related to the four sister specialties of anesthesiology, pain management, intensive care and resuscitation to the healthcare practitioners in the target area. The journal has adopted a comprehensive peer review system to promote scholarship. It has since thrived despite innumerable constraints, and now boasts to be one of the leading research oriented journals of the region. Our area of circulation encompasses whole of South Asia and the Middle East and the journal is indexed / abstracted by most of the international indexing agencies.

Join the conversation about this journal

**Submit Paper for Publication**

---

IJFMR - Academic Journal Op


Quartiles

FIND SIMILAR JOURNALS

<p>1</p> <p><b>Saudi Journal of Anaesthesia</b></p> <p>IND</p>	<p>2</p> <p><b>Egyptian Journal of Anaesthesia</b></p> <p>GBR</p>	<p>3</p> <p><b>Brazilian Journal of Anesthesiology (English)</b></p> <p>BRA</p>	<p>4</p> <p><b>Revista Mexicana de Anestesiologia</b></p> <p>MEX</p>	<p>5</p> <p><b>BMC A</b></p> <p>GBR</p>			
84%		80%		80%		78%	
similarity		similarity		similarity		similarity	

## Submit Paper for Publication

IJFMR - Academic Journal Op



**Anaesthesia, Pain and Intensive Care**

**Q4** Anesthesiology and Pain Medicine  
best quartile

**SJR 2022**  
**0.14**

powered by scimagojr.com


← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimaç
```

**SCImago Graphica**

Explore, visually communicate and make sense of data with our **new data visualization tool.**



Metrics based on Scopus® data as of April 2023

Register (<https://www.apicareonline.com/index.php/APIC/user/register>)Login (<https://www.apicareonline.com/index.php/APIC/login>)

Anaesthesia, Pain &amp; Intensive Care

(<https://www.apicareonline.com/index.php/index>)

## CURRENT

([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ISSUE/CURRENT](https://www.apicareonline.com/index.php/APIC/ISSUE/CURRENT))

## ARCHIVES

([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ISSUE/ARCHIVE](https://www.apicareonline.com/index.php/APIC/ISSUE/ARCHIVE))

ABOUT ▾ GUIDELINES FOR AUTHORS ▾

## ANNOUNCEMENTS

([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ANNOUNCEMENT](https://www.apicareonline.com/index.php/APIC/ANNOUNCEMENT))OLD SITE ([HTTP://WWW.APICAREONLINE.COM/OLDSITE/WORDPRESS/EDITORIAL-BOARD/](http://www.apicareonline.com/oldsite/wordpress/editorial-board/))

HOME ([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/INDEX](https://www.apicareonline.com/index.php/APIC/INDEX)) / Editorial Team

## Editorial Team

## PATRON




**Brig (Retd) M. Salim, SI (M), DA, FFARCS, FCPS, PhD**  
 Professor of Anesthesiology & Pain Medicine  
 Founder member, Pakistan Society of Anesthesiologists (PSA)  
 Founder, Past President & Patron, Society for Treatment & Study of Pain (STSP®)  
 E-mail: [brigsaleem1@gmail.com](mailto:brigsaleem1@gmail.com) (<mailto:brigsaleem1@gmail.com>)

## EDITOR-IN-CHIEF



**Tariq Hayat Khan, MBBS, DA, MCPS, FCPS**  
 Consultant Anesthesiologist & Pain Specialist,  
 President, Pakistan Resuscitation Society (PARES)  
 Cell: +92-321-5149709  
 E-mail: [apicarejournal@gmail.com](mailto:apicarejournal@gmail.com) (<mailto:apicarejournal@gmail.com>)

## Senior Editor:



**Fauzia Anis Khan, LRCP, MRCS, FRCA, MCPS, FCPS, (Pakistan)**  
 Department of Anaesthesia, The Aga Khan University, Karachi  
 Ex-HoD/Interim Associate Dean, Postgraduate Medical Education, Aga Khan University,  
 Karachi (Pakistan)  
 E-mail: [fauzia.khan@aku.edu](mailto:fauzia.khan@aku.edu) (<mailto:fauzia.khan@aku.edu>)

## Associate Editors

**AKM Akhtar uz Zaman (Bangladesh)**  
 Professor of Neuroanaesthesia,  
 Fellowship in Anaesthesia and Pain Medicine in Tokyo (Japan).  
 E-mail: [akm.akhtaruzzaman@bsmmu.edu.bd](mailto:akm.akhtaruzzaman@bsmmu.edu.bd) (<mailto:akm.akhtaruzzaman@bsmmu.edu.bd>)

**Pranav Bansal, MBBS, MD (Anesthesiology) (India)**  
 Professor & Head, Dept. of Anesthesiology  
 BPS Govt. Medical College, Khanpur Kalan, Sonapat, Haryana, (India)  
 E-mail: [pranavbansal1@gmail.com](mailto:pranavbansal1@gmail.com) (<mailto:pranavbansal1@gmail.com>)

**Logan Danielson, MD, MBA (USA)**  
 Children's Hospital of Michigan, Detroit, MI  
 Research Assistant for Michigan Pediatric Surgical Associates, Detroit, MI (USA)  
 E-mail: [logandanielson@gmail.com](mailto:logandanielson@gmail.com) (<mailto:logandanielson@gmail.com>)

**ASSISTANT EDITORS**

**Muhammad Faisal Jafar**, MBBS, MCPS, FCPS (Pak), FRCA (UK)  
(mailto:faisaljafar@yahoo.com) Consultant Anaesthetist, St John's Hospital, Livingston, Scotland

Address: 58c Gracemount Drive, Edinburgh, EH17 8DA (UK).  
E-mail: faisaljafar@yahoo.com (mailto:faisaljafar@yahoo.com)

**Somaye Pouy**

PhD Student of Nursing Education  
Instructor at Guilan University of Medical Sciences, Rasht, Iran  
**Email:** Somayepouy@gmail.com (mailto:Somayepouy@gmail.com)

**Mishal Fatima**, MBBS, FCPS (I) (Pakistan)

Department of Surgery,  
Islamabad Medical Complex, Islamabad (Pakistan)  
E-mail: mishalfati@gmail.com (mailto:mishalfati@gmail.com)

**STATISTICIAN****Shamail Alam**

Punjab Institute of Cardiology, Lahore (Pakistan)  
E-mail: shamailalam@gmail.com (mailto:shamailalam@gmail.com)

**EDITORIAL BOARD Members**

**Aliya Ahmed**, FFARCSI (Pakistan)

Professor of Anaesthesiology  
Director, Residency Programme in Anaesthesia, Agha Khan University Hospital Karachi (Pakistan).  
E-mail: aliya.ahmed@aku.edu (mailto:aliya.ahmed@aku.edu)

**Arshad Taqi**, FCPS, (Pakistan)

Professor of Anesthesiology,  
Hameed Latif Hospital & Medical College, Garden Town, Lahore  
Consultant Anesthesiologist, Kaul Anesthesia Associates (Pvt) Ltd., Lahore (Pakistan)  
E-mail: arshadtaqi@gmail.com (mailto:arshadtaqi@gmail.com)

**Gauhar Afshan**, MBBS, MCPS, FCPS. (Pakistan)

Professor of Anesthesiology & Pain Medicine  
Agha Khan University Hospital, Karachi.  
E-mail: gauhar.afshan@aku.edu (mailto:gauhar.afshan@aku.edu)

**Fazal Hameed Khan**, MBBS, MCPS, FCPS. (Pakistan)

Professor of Anesthesiology  
Interim Chair, Department of Emergency Medicine,  
Aga Khan University Hospital Karachi.  
E-mail: Fazal.hkhan@aku.edu (mailto:Fazal.hkhan@aku.edu)

**Anuja Unnathie Abayadeera**, MD, FRCA (Sri Lanka)

Professor in Anesthesiology, University of Colombo, Sri Lanka  
Honorary Consultant Anaesthetist, University Surgical Unit, National Hospital of Sri Lanka, Colombo.  
E-mail: anujaa@sltnet.lk (mailto:anujaa@sltnet.lk); anuja@srg.cmb.ac.lk (mailto:anuja@srg.cmb.ac.lk)

**Hanik Badriyah Hidayati** (Indonesia)

Departement of Neurology,  
Medical Faculty of Airlangga University / Soetomo General Hospital Surabaya, East Java, Indonesia.  
E-mail: hanikhidayati@yahoo.com

**Arzu Irban**, MD, DESA (Turkey)

Professor of Anesthesiology & Reanimation, Medipol Mega University Hospital.  
Member of Scientific Committee of Complementary & Alternative Medicine  
E-mail: arzu.irban@yahoo.com (mailto:arzu.irban@yahoo.com)

**Dario Galante**, MD, (Italy)

President, SIAATIP (Società Italiana di Anestesia, Analgesia e Terapia Intensiva Pediatrica),  
Head, Pediatric and Neonatal Anesthesia, University Department of Anesthesia and Intensive Care, University Hospital "Ospedali Runiti" of Foggia, Italy  
Email: dario.galante@tin.it (mailto:dario.galante@tin.it); siaatip@siaatip.it (mailto:siaatip@siaatip.it);

**Romana Shaida Durrani**

Dip Pain Medicine, EDAIC, FCAI Final, MCAI (Primary), DA, DHP&M  
Consultant Anaesthesia & Pain Medicine  
Shaukat Khanum Memorial Hospital, Lahore (Pakistan)  
Cell: +92 334 4774773  
E-mail: romanadurrani@gmail.com

**Ashish C. Sinha, M.D., PhD, MBA (USA)**

Certified American Board of Anesthesiology  
Vice Chairman, Anesthesiology and Perioperative Medicine, Drexel University College of  
Medicine, Hahnemann University Hospital, Philadelphia  
E-mail: ashish.sinha@gmail.com (mailto:ashish.sinha@gmail.com)

**Giustino Varrassi (Italy)**

President of the World Institute of Pain  
President, Paolo Procacci Foundatio  
Address: Frazione San Vittorino 67010 L'Aquila, Italy  
Phone: +39 0862 1966010  
E-mail: giuvarr@gmail.com

**Joseph Drew Tobias, MD (USA)**

Chairman, Department of Anesthesiology & Pain Medicine Professor of anesthesiology and  
pediatrics at the Ohio State University.  
E-mail: joseph.tobias@nationwidechildrens.org (<http://nationwidechildrens.org/>)

**Somchai Amorniyotin (Thailand)**

Somchai Amorniyotin, MD, FRCAT, is currently Associate Professor of anesthesiology at  
Department of Anesthesiology and Siriraj GI Endoscopy Center, Faculty of Medicine Siriraj  
Hospital, Mahidol University, Bangkok. He qualified graduation in medicine in 1989, and  
completed residency in anesthesiology in 1996. He is certified by Thai Boards of Family  
Medicine and anesthesiology. He has held various academic positions in anesthesiology. He has  
special interest in anesthesia for gastrointestinal endoscopy, TIVA, TCI, ambulatory anesthesia,  
airway management, and acute postoperative pain management.  
Dr Somchai has won various awards and decorations in the field of research and innovation. He  
has been a member of editorial and review boards of numerous scientific journals, and has been  
an author of many, book chapters and numerous research papers.  
E-mail: somchai.amo@mahidol.ac.th (<http://mahidol.ac.th/>)

**Tolga Ergonenc, MD**

Anesthesiology and Intensive Care Specialist  
Secretary: Akyazi Pain Center  
E-mail: tolgaergonenc@gmail.com  
Telephone: 090 532 485 98 40

**Govind R.C. Rajan MBBS, FAACD, FASA (USA)**

Professor Clinical Series Step-III  
Director of Clinical Affairs  
Operations officer of Operating Rooms  
Chief of Liaison Corps: Surgical Services  
Chair Anesthesiology Critical Care Fellowship Competency Committee  
Department of Anesthesiology and Perioperative Care, University of California, Irvine Health,  
333, City Blvd, W STE 2150  
Orange, CA, 92868  
Office: 7144565463; Cell: 3148039398  
E-mail: [grajan@uci.edu](mailto:grajan@uci.edu) (mailto:grajan@uci.edu); [govindrcajan@gmail.com](mailto:govindrcajan@gmail.com)  
(mailto:govindrcajan@gmail.com)

**Yasuhiro Morimoto, MD (Japan)**

Independent Researcher of Anesthesiology  
Associate Editor, Journal of Anesthesia (official Journal of JSA)  
E-mail: yasumorimo@gmail.com (<http://gmail.com/>)

**SUBMIT YOUR ARTICLES CLICK HERE**  
(<HTTPS://WWW.EJMANAGER.COM/MY/APIC/>)

---

**ADVERTISE WITH US**

✉ [apicjournal@gmail.com](mailto:apicjournal@gmail.com)  
✉ [apicare@yahoo.com](mailto:apicare@yahoo.com)  
☎ +92-321-5149709

**LATEST NEWS / EVENTS**

Register (<https://www.apicareonline.com/index.php/APIC/user/register>)Login (<https://www.apicareonline.com/index.php/APIC/login>)

Anaesthesia, Pain &amp; Intensive Care

(<https://www.apicareonline.com/index.php/index>)

CURRENT

([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ISSUE/CURRENT](https://www.apicareonline.com/index.php/APIC/ISSUE/CURRENT))

ARCHIVES


([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ISSUE/ARCHIVE](https://www.apicareonline.com/index.php/APIC/ISSUE/ARCHIVE))

ABOUT ▾ GUIDELINES FOR AUTHORS ▾

ANNOUNCEMENTS

([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ANNOUNCEMENT](https://www.apicareonline.com/index.php/APIC/ANNOUNCEMENT))OLD SITE ([HTTP://WWW.APICAREONLINE.COM/OLDSITE/WORDPRESS/EDITORIAL-BOARD/](http://www.apicareonline.com/oldsite/wordpress/editorial-board/))
 

HOME ([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/INDEX](https://www.apicareonline.com/index.php/APIC/INDEX)) /  
 ARCHIVES ([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ISSUE/ARCHIVE](https://www.apicareonline.com/index.php/APIC/ISSUE/ARCHIVE)) /  
 Vol 26 No 1 (2022): February 2022

(<https://www.apicareonline.com/index.php/APIC/issue/view/73>)

## EDITORIAL VIEWS

### Data science and its application in anesthesiology

(<https://www.apicareonline.com/index.php/APIC/article/view/1757>)

Shemila Abbasi, Usama Ahmed, Fauzia Anis Khan

1-3

PDF  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1757/2657](https://www.apicareonline.com/index.php/APIC/ARTICLE/VIEW/1757/2657))HTML  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1757/2682](https://www.apicareonline.com/index.php/APIC/ARTICLE/VIEW/1757/2682))

### Anesthesia without opioids

(<https://www.apicareonline.com/index.php/APIC/article/view/1758>)

Mohsin Nazir Butt, Asma Faraz, Maheen Fazal

4-7

PDF  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1758/2658](https://www.apicareonline.com/index.php/APIC/ARTICLE/VIEW/1758/2658))HTML  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1758/2683](https://www.apicareonline.com/index.php/APIC/ARTICLE/VIEW/1758/2683))

## ORIGINAL RESEARCH

### Effect of three different doses of intrathecal dexmedetomidine on subarachnoid block: a prospective randomized double-blind trial

(<https://www.apicareonline.com/index.php/APIC/article/view/1759>)

Ashita Mowar, Vishwadeep Singh, Akhilesh Pahade, Geeta Karki

8-13




**surgeries: a randomized clinical trial**<https://www.apicareonline.com/index.php/APIC/article/view/1765>

44-52

Mohamed Mahmoud Hassan, Emad Gerges Saleh, Norma Osama Abdalla, Noha Hassan  
Radwan, Ekramy Mansour Abdelghfar

 PDF  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1765/2665](https://www.apicareonline.com/index.php/APIC/article/view/1765/2665))

 HTML  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1765/2690](https://www.apicareonline.com/index.php/APIC/article/view/1765/2690))

**Prognostic significance of non-thyroidal illness syndrome in sepsis and septic shock cases: a systematic review and meta-analysis**<https://www.apicareonline.com/index.php/APIC/article/view/1768>

54-62

Rio Wironegoro, Nabila Ananda Kloping, Andro Pramana Witarto, David Nugraha, Niwanda  
Yogiswara, Kevin Luke, Yudhistira Pradnyan Kloping, Maulydia Maulydia, Soebagijo Adi

 PDF  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1768/2666](https://www.apicareonline.com/index.php/APIC/article/view/1768/2666))

 HTML  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1768/2691](https://www.apicareonline.com/index.php/APIC/article/view/1768/2691))

**Safety and efficacy of LMA Supreme™ vs. LMA ProSeal™ for ambulatory surgeries in adult patients**<https://www.apicareonline.com/index.php/APIC/article/view/1769>

63-68

Amanjot Singh, Jaskirat Kaur, Sarvjeet Kaur, Kewal Krishan Gupta

 PDF  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1769/2667](https://www.apicareonline.com/index.php/APIC/article/view/1769/2667))

 HTML  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1769/2692](https://www.apicareonline.com/index.php/APIC/article/view/1769/2692))

**An online study of knowledge and practices of local anesthetic systemic toxicity among doctors in Sri Lanka**<https://www.apicareonline.com/index.php/APIC/article/view/1770>

69-74

B. M. Munasinghe, Nishanthan Subramaniam, Nimalan Srisothinathan, B. D. W.  
Jayamanne

 PDF  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1770/2668](https://www.apicareonline.com/index.php/APIC/article/view/1770/2668))

 HTML  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1770/2693](https://www.apicareonline.com/index.php/APIC/article/view/1770/2693))

**A randomized controlled trial to study the effect of a pediatric anesthesia comic information leaflet on preoperative anxiety in children**<https://www.apicareonline.com/index.php/APIC/article/view/1771>

75-80

Malavika M. Kulkarni, Shwetha Pradeep, Madhu Rao, Muralidhar M. Kulkarni

 PDF  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1771/2669](https://www.apicareonline.com/index.php/APIC/article/view/1771/2669))

 HTML  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1771/2694](https://www.apicareonline.com/index.php/APIC/article/view/1771/2694))

**A comparative randomized study of awareness during two anesthetic induction techniques in old aged patients using isolated forearm technique**<https://www.apicareonline.com/index.php/APIC/article/view/1772>

81-88

Tamer Hamed Ibrahim, Ahmed H. Ayoub, Ibrahim Mohamed Ibrahim, Mohamed  
Abdulmohsen Abdulnaiem Ismaiel, Raham Hasan Mostafa

PDF  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1785/2681](https://www.apicareonline.com/index.php/APIC/article/view/1785/2681))

HTML  
([HTTPS://WWW.APICAREONLINE.COM/INDEX.PHP/APIC/ARTICLE/VIEW/1785/2705](https://www.apicareonline.com/index.php/APIC/article/view/1785/2705))

## EDITORIAL

Published - Data Science and its Application in Anaesthesiology

(<https://www.apicareonline.com/index.php/APIC/article/view/1742>)

Shemila Abbasi, Usama Ahmed, Fauzia Anis Khan

**SUBMIT YOUR ARTICLES CLICK HERE**  
([HTTPS://WWW.EJMANAGER.COM/MY/APIC/](https://www.ejmanager.com/my/apic/))

## ADVERTISE WITH US

✉ [apicjournal@gmail.com](mailto:apicjournal@gmail.com)

✉ [apicare@yahoo.com](mailto:apicare@yahoo.com)

☎ +92-321-5149709

## LATEST NEWS / EVENTS

**Online Abstracts Deadline**  
**10 Feb 2023**  
[www.psamultan.org.pk](http://www.psamultan.org.pk)

**Online Registration Closing Date**  
**10 Feb 2023**  
[www.psamultan.org.pk](http://www.psamultan.org.pk)

**5th Multan Conference of Anesthesia - Critical Care & Pain**  
**MCA-2023**  
New Era of Innovations & Advancements in Anesthesia, Education & Safety  
**24 - 25 February 2023**  
Nishtar Medical University, Multan

For Further Information Visit our Website or Contact  
Department of Anaesthesia, Nishtar Hospital, Multan,  
Ph: 0333-6203152, 0333-5416916, Email: [mcamultan1@gmail.com](mailto:mcamultan1@gmail.com),  
[info@psamultan.org.pk](mailto:info@psamultan.org.pk), Website: [www.psamultan.org.pk](http://www.psamultan.org.pk)

Follow Us  
 @psamultan  
 @psamultan  
 @psamultan  
 @psamultan

### Regional Office (Pakistan)

📍 Dept of Anaesthesia and Pain Management, Aga Khan University Hospital, Stadium Road, Karachi (Pakistan)

✉ [fauzia.khan@aku.edu](mailto:fauzia.khan@aku.edu)

☎ +92-21-34864631/4331

### Head Office

📍 Editor, "APICAREHQ" 25-E, Ibn-e-Sina Road, G-10/3, Islamabad-44000, Pakistan

✉ [apicjournal@gmail.com](mailto:apicjournal@gmail.com)

✉ [apicare@yahoo.com](mailto:apicare@yahoo.com)

☎ +92 321 514 9709

### FOLLOW US

(<https://www.facebook.com/apicare>)

(<https://twitter.com/apicarejournal>)

(<https://www.youtube.com/channel/UCOykrTVMTA55La1LDnSSMQ>)

Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)  
(<http://creativecommons.org/licenses/by-nc/4.0/>)

© Anaesthesia, Pain & Intensive Care, 2010-2013

Powered By QuaidTech (<http://quaidtech.com/>)

## ORIGINAL RESEARCH

## INTENSIVE CARE

# Prognostic significance of non-thyroidal illness syndrome in sepsis and septic shock cases: a systematic review and meta-analysis

Rio Wironegoro<sup>1</sup>, Nabila Ananda Kloping<sup>2</sup> ✉, Andro Pramana Witarto<sup>2</sup> ✉, David Nugraha<sup>2</sup> ✉, Niwanda Yogiswara<sup>2</sup> ✉, Kevin Luke<sup>2</sup> ✉, Yudhistira Pradnyan Kloping<sup>2</sup> ✉, Maulydia Maulydia<sup>3</sup> ✉, Soebagijo Adi<sup>1</sup> ✉

**Author affiliation:**

1. Department of Internal Medicine, Division of Endocrinology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
2. Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
3. Department of Anaesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

**Correspondence:** Rio Wironegoro, {ORCID:0000-0002-8756-3273}; E-mail: [rio18378@gmail.com](mailto:rio18378@gmail.com); Tel: +62-811312146

## Abstract

**Background:** This study aimed to assess non-thyroidal illness syndrome (NTIS) as a prognostic determinant in patients with sepsis, severe sepsis, and septic shock by evaluating thyroid hormone (TH) levels.

**Methodology:** A systematic search was performed through electronic databases including PubMed, Embase, Scopus, and Medline. Following medical subject headings (MeSH) and free-text terms: "euthyroid sick syndrome" or "Euthyroid Sick Syndromes" or "non-thyroidal illness syndrome" or "non-thyroidal illness syndrome" or "sick euthyroid syndrome" or "low T3 syndrome" or "low tri-iodothyronine syndrome" AND "sepsis" or "septic shock" or "systemic inflammatory response syndrome" or "septicemia" or "bacteremia". Boolean operators' combinations were applied to broaden and narrow the search results. Investigators independently reviewed the search results. For the purpose of the meta-analysis each thyroid hormone level was converted into the same unit: nmol/L for T3, T4 and rT3;  $\mu$ IU/mL for TSH; and pmol/L for fT3 and fT4. Statistical analysis was performed using *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC.

**Results:** A total of 843 patients from 9 studies were included in this analysis. In septic patients, the lowest effect size of thyroid function parameter was TSH ( $g = 2.05$ ; 95% CI = 1.56-2.54), while T3, fT3, and fT4 had the lowest effect size in severe septic patients ( $g$  [95%CI]: 0.83 [0.22-1.44]; 1.92 [0.57-3.27]; 1.00 [0.87-1.13]). Patients with septic shock had the highest effect size of TSH ( $g = 2.08$ ; 95% CI = 1.54-2.61) and fT4 ( $g = 9.26$ ; 95% CI = 0.98-17.53). Meanwhile, the lowest was T4 ( $g = 65.60$ ; 95% CI = 64.63-66.57) and rT3 ( $g = 0.29$ ; 95% CI = 0.24-0.34). A lower effect size of T3 ( $g = 0.83$ ; 95% CI = 0.76-0.91), T4 ( $g = 59.48$ ; 95% CI = 57.92-61.04), fT3 ( $g = 2.25$ ; 95% CI = 1.83-2.66), and fT4 ( $g = 9.19$ ; 95% CI = 1.56-16.81) were found in non-survivor groups.

**Conclusion:** Thyroid hormone levels differ according to the severity of sepsis in septic patients. Non-thyroidal illness syndrome is a prognostic factor in septic patients and is associated with the risk of the mortality.

**Abbreviations:** ESS - Euthyroid Sick Syndrome; NTIS - Non-Thyroidal Illness Syndrome; Tg - Thyroglobulin

**Key words:** Non-thyroidal illness syndrome; Euthyroid sick syndrome; Sepsis; Septic shock; Prognosis

**Citation:** Wironegoro R, Kloping NA, Witarto AP, Nugraha D, Yogiswara N, Luke K, KlopingYP, Maulydia M, Adi S. Prognostic significance of non-thyroidal illness syndrome in sepsis and septic shock cases: a systematic review and meta-analysis. *Anaesth. pain intensive care* 2021;26(1):54-62. DOI: 10.35975/apic.v26i1.1768

**Received:** July 16, 2021, **Reviewed:** December 15, 2021, **Accepted:** December 28, 2021

## 1. Introduction

During stress the body creates a metabolic response regulated by a complex combination of pathways; neuroendocrine response being one of the main components that is triggered. Within seconds to minutes, the sympathetic nervous system is stimulated, followed by activation of the hypothalamic-pituitary axis. Atypical thyroid hormone findings, as part of the hypothalamic-pituitary-thyroid axis, are frequently detected in hospitalized elderly or critically ill patients.<sup>1</sup>

<sup>2</sup> This condition is often recognized as Euthyroid Sick Syndrome (ESS) or Non-Thyroidal Illness Syndrome (NTIS). ESS (or NTIS) is characterized by a decrease in triiodothyronine (T3), and thyroxine (T4) without changes in thyroid-stimulating hormone (TSH), or a history of thyroid disease.<sup>3</sup> This neuroendocrine response to critical illness can be seen in septic patients.<sup>4</sup>

Sepsis is a significant healthcare issue, with up to 300 cases per 100,000 people annually in the USA.<sup>5</sup> Despite many advances in both treatment and prevention, sepsis caused a substantial financial burden and remained one of the significant causes of mortality in critically ill patients.<sup>5</sup> Some studies suggested that thyroid hormone changes can be correlated with poor outcomes in septic patients.<sup>4</sup> However, we found that studies tend not to measure all thyroid functions tests, e.g., T3, T4, TSH, free T3 (fT3), free T4 (fT4), reverse T3 (rT3), and thyroglobulin (Tg); and thus their recommendations for serum tests that can be used as a prognostic factor for sepsis are inconsistent.<sup>6,7</sup> Although a systematic review on low thyroid hormone and sepsis has been done earlier, but that study did not categorize the outcome of sepsis and septic shock.<sup>8</sup>

Considering the difference in prognosis, we attempted to separate the prognostic effect of sepsis and septic shock in this review. We also evaluated the updated quantitative assessment of the clinical significance of NTIS in sepsis, severe sepsis, and septic shock patients.

## 2. Methodology

This systematic review and meta-analysis has been registered in the PROSPERO public database (CRD42021227931).

### Database Search Strategy

We conducted this systematic review according to the Cochrane Handbook for Systematic Review of Interventions and based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statements.<sup>9,10</sup> We systematically searched PubMed, Scopus, Embase, and Medline databases using the following medical subject headings (MeSH) and free-text terms: "euthyroid sick syndrome" or "Euthyroid

Sick Syndromes" or "non-thyroidal illness syndrome" or "non-thyroidal illness syndrome" or "sick euthyroid syndrome" or "low T3 syndrome" or "low triiodothyronine syndrome" AND "sepsis" or "septic shock" or "systemic inflammatory response syndrome" or "septicemia" or "bacteremia". Boolean operators' combinations were applied to broaden and narrow the search results. The search was limited to human subjects and articles written in English.

### Eligibility Criteria

We included all cohort (prospective or retrospective) studies, cross-sectional studies, case-control studies, or controlled trial studies. All studies with the following criteria were included in the analysis: 1) adult patients with sepsis, severe sepsis, SIRS, and septic shock, while also diagnosed with ESS or NTIS; 2) Where the primary outcome was mortality rate; 3) The secondary outcomes included the prevalence of ESS and a descriptive result of overall thyroid function. Subsequently, the exclusion criteria were as follows: case reports or case series, editorials, reviews, and animal studies, as well as patients that were given any pharmacologic agents or that had an endocrine abnormality that could have confounded the outcomes.

### Data Synthesis and Quality Assessment

Multiple investigators (NY, KL, AP, NA, and DN) independently reviewed the search results. Duplicate records were removed manually by NA. Then, the primary screening was done by assessing each study's title and abstract. Then, the eligibility of each study was decided by multiple investigators. The reason for exclusion was reported. Any disagreements between authors were discussed with final decisions made by investigators who were experts in the area. Furthermore, we extracted the data regarding the author/s and the year of publication, study design and location, total sample size, ages, Thyroid Function Tests (TFT), measurement method, and mortality.

To evaluate the quality of included studies, we performed quality assessments for bias using Newcastle-Ottawa Scale (NOS) by two authors (NA and DN) collaboratively.<sup>11</sup> Any disagreements between investigators were adjudicated by a third investigator (KL).

### Statistical Analysis

The studies in this review excluded patients with precursor thyroid diseases, endocrine abnormality, thyroid hormone therapy or replacement, and amiodarone therapy that would affect thyroid levels. All thyroid values that were calculated in the meta-analysis were extracted from the baseline characteristics (during admission or diagnosis of sepsis). Studies that had thyroid evaluation outcomes were divided into each

Table 1: Particulars of the included studies

Authors, Year	Study Design	Country	Population (n)	Age (y); Male %	Type of TFT (timing of measurement)	Study definition for ESS/NTIS/Low T3	Mortality (%)
Cornu et al., 2020 [13]	Prospective Cohort	Argentina	27 [septic shock]	55.9 ± 16; 48.9%	TSH, T3, T4 (on admission/diagnosis, day 7, day 14, day 21)	T3 < 80 ng/dL	36.7% (28-days mortality)
Gore et al., 1998 [14]	Prospective Cohort	USA	6 [severe sepsis]	45.5; N/A	TSH, fT4, fT3, T3 (on admission)	Low plasma concentrations of both total and free T3, while rT3, T4, and TSH levels were normal.	N/A
Hosny et al., 2015 [7]	Prospective Cohort	Egypt	[sepsis (36), severe sepsis (22), septic shock (22)]	55.8 ± 17; 75%	TSH, fT4, fT3 (on admission/day 1, day 5)	N/A	48.75% (ICU mortality)
Meyer et al., 2011 [6]	Prospective Cohort	Switzerland	103 [sepsis (22), SIRS (50), severe sepsis (15), septic shock (16)]	59 (46-68.5); 54.4%	fT4, T3 (on admission/day ), follow up day 2)	Low triiodothyronine (below normal range)	23.3% (In hospital mortality)
Monig et al., 1999 [15]	Prospective Cohort	Germany	9 [sepsis]	61; 55.5%	TSH, fT4, T3, T4 (on admission/day 1)	N/A	N/A
Padhi et al., 2018 [16]	Prospective Cohort	India	360 [sepsis, severe sepsis, septic shock]	70 ± 13.4; 58.3%	TSH, fT4, fT3, T3, T4, rT3 (within 24h of ICU admission)	(i) Low T3 and normal or high T4, (ii) combination of low T3 and low T4	36.1% (28-days mortality)
Palazzo et al., 1991 [17]	Prospective Cohort	Switzerland	14 [septic shock]	52.92; N/A	TSH, fT4, fT3, rT3; Each morning	Low T3, normal TSH and rT3.	42.8% (In hospital mortality)
Rodriguez-Perez et al., 2008 [18]	Prospective Cohort	Netherlands	13 [septic shock]	73; 46%	TSH, fT4, fT3, rT3 (5 days after ICU admission)	N/A	N/A
Todd et al., 2012 [12]	Retrospective Cohort	USA	231 [sepsis (39), severe sepsis (131), septic shock (61)]	59 ± 3; 43%	T3, T4, TSH (on admission)	N/A	18% (In hospital mortality)

N/A = not available; SIRS = Systemic inflammatory response syndrome

population (sepsis, severe sepsis, septic shock), were measured in each subgroup in the forest plot as a one arm analysis. Otherwise, they were calculated in the survivor or non-survivor subgroups only. For the purpose of the meta-analysis each thyroid hormone level was converted into the same unit: nmol/L for T3, T4 and rT3;  $\mu$ IU/mL for TSH; and pmol/L for fT3 and fT4.

The estimate analysis was effect size (ES) with its 95% CI for binary and continuous outcomes. If the included studies had no or small heterogeneity ( $p > 0.1$ ,  $I^2 < 50\%$ ), the fixed-effects inverse-variance model was chosen to synthesize data. When the heterogeneity was found to be significant ( $p < 0.1$ ,  $I^2 > 50\%$ ), we chose the DerSimoian-Laird model. Statistical analysis was

performed using *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC.

### 3. Results

#### Overview of Literature Search

During the initial search, a total of 286 studies were identified. Two additional studies were included from a previous systematic review. Of these, 138 studies were not duplicative. 110 studies were excluded based on study objectives, leaving 28 studies for eligibility assessment. Finally, nine studies were included for qualitative and quantitative analysis after excluding 19 studies. This process has been summarized in Figure 1.

**Table 2: Normal thyroid function test values in different studies**

Authors, Year	Measurement device	T3	T4	TSH	fT3	fT4	rT3
Cornu et al., 2020	Electro chemiluminescence	80 - 200 ng/dL (1.2 - 3.0 nmol/L)	5.1 - 14.1 µg/dL (65.6 - 181.5 nmol/L)	0.27 - 4.2 µIU/mL	N/A	0.93 - 1.7 ng/dL (11.9 - 21.8 pmol/L)	N/A
Gore et al., 1998	Radioimmunoassay	90 - 190 ng/dl (1.3 - 2.9 nmol/L)	4.5 - 12.0 mcg/dl (58 - 154 nmol/L)	0.32 ± 5 µIU/ml	125 - 300 pg/dl (1.9 - 4.6 pmol/L)	N/A	10 - 24 ng/dL (0.15 - 0.37 nmol/L)
Hosny et al., 2015	ELISA	N/A	N/A	0.3 - 5.50 mIU/L (0.3 - 5.50 µIU/ml)	1.7 - 4.5 pmol/L	0.8 - 2 pmol/L	N/A
Meyer et al., 2011	Electro chemistry-luminescence immunoassay	0,3 - 10 nmol/L	N/A	N/A	N/A	0.3 - 100 pmol/L	N/A
Monig et al., 1999	Chemiluminescence immunoassay	N/A (ng/ml)	N/A (ng/ml)	N/A (µIU/mL)	N/A	N/A (ng/dL)	N/A
Padhi et al., 2018	IMMULITE 2000 (TSH and thyroid hormone), chemiluminescence immunoassay (rT3)	1.1 - 2.6nmol/L	65 - 130nmol/L	0.27 - 4.6µIU/mL	3.7 - 7.3 pmol/L	12-24 pmol/L	0.15 - 0.43nmol /L
Palazzo et al., 1991	Coated tube RIA (TSH), radioimmunoassay (fT4, fT3), reverse radioimmunoassay (rT3)	N/A	N/A	0.5 - 4 µIU/mL	2.2 - 7.2 pmol/L	10 - 26 pmol/L	103 - 508 pg/ml (0.16 - 0.78 nmol/L)
Rodriguez-Perez et al., 2008	Chemiluminescence	N/A	N/A	0.41 - 4.94 mU/L (0.41 - 4.94 µIU/ml)	3.89 - 6.60 pmol/L	10.94 - 21.75 pmol/L	0.23 - 0.54 nmol/L
Todd et al., 2012	N/A	60 - 181 ng/dL (0.9 - 2.7 nmol/l)	0.8 - 1.8 ng/dL (64 - 154 nmol/L)	0.55 - 4.78 µIU/mL	N/A	N/A	N/A

N/A = not available

### Characteristics and Eligibility of Selected Studies

A total of 843 patients from 9 unique studies were included in this analysis. The detailed characteristics are displayed in Table 1. Most of the studies were prospective cohort studies, except a study by Todd *et al.* (2012).<sup>12</sup> The mean age of participants ranged from 45.5 to 73 y and the gender was predominately male. Thyroid function (TSH, T3, T4, fT3, or fT4) was mostly measured during admission using various methods. The studies' definition of sepsis was assembled in Supplemental Table S1. SIRS (systemic inflammatory response syndrome) was only classified in one study by Meyer *et al.* (2011); thus, it was not elaborated further

in the forest plot subgroup.<sup>6</sup> The crude mortality rate of the population in this review was 23.3 - 48.75%. Measured death was limited from in-ICU death, in-hospital death to 28-day follow-up.

Each study's normal thyroid function values are listed in Table 2. Different laboratory tests for measuring TFTs have different reference ranges. The study by Meyer *et al.* (2011) had a very high upper range in both T3 and fT4.<sup>6</sup> The normal fT4 and fT3 values for Hosny *et al.* (2015) were relatively different from the others, as was the fT3 level from Gore *et al.* (1998).<sup>7, 14</sup> Monig *et al.*

**Table 3: Risk of bias assessment using New-Castle Ottawa Scale (NOS)**

Author	Selection		Comparability			Outcome		NOS score	Interpretation of Quality
	Selection of the Non-Exposed Cohort Representativeness of the Exposed Cohort	Ascertainment of Exposure	Demonstration That Outcome of Interest Was Not Present at Start of Study	Comparability of cohorts on the basis of the design or analysis	Additional factors adjustment	Was follow-up long enough for outcomes to occur	Assessment of outcome		
Cornu, 2020	*	*	*	*	*	*	*	8	Good
Gore, 1998	*	*	*	*	*	*	*	6	Poor
Hosny, 2015	*	*	*	*	*	*	*	8	Good
Meyer, 2011	*	*	*	*	*	*	*	8	Good
Monig, 1999	*	*	*	*	*	*	*	7	Good
Padhi, 2018	*	*	*	*	*	*	*	8	Good
Palazzo, 1991	*	*	*	*	*	*	*	9	Good
Rodriguez, 2008	*	*	*	*	*	*	*	6	Poor
Todd, 2012	*	*	*	*	*	*	*	7	Good


(1999) did not include their TFT reference ranges in their study.<sup>15</sup>

**Quality Assessment**

Based on the NOS criteria, most studies were considered to have good methodological quality as shown in Table 3. The exceptions to this were the studies by Gore *et al.* and Rodriguez *et al.* due to their inadequate quality in comparability and outcome, respectively.<sup>14, 18</sup>

**Thyroid Function Parameter Evaluation**

This single-arm meta-analysis included different total numbers of patients in each thyroid function parameter: 923 patients in T3 and TSH, 736 patients in T4, 443 patients in fT3, 540 patients in fT4, and 269 patients in rT3 (Table 4). In septic patients, the lowest effect size of thyroid function parameter was only found in TSH ( $g = 2.05$ ; 95% CI = 1.56-2.54), while the highest was



**Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flowchart**

Table 4: Pooled analysis of thyroid function parameters.

Thyroid Function Parameter	Study Population	Sample Size (n)	Effect Size (g)	95% CI	Heterogeneity		
					I <sup>2</sup> (%)	H <sup>2</sup>	p-value
T3 (nmol/L)	Sepsis	92	1.09	0.93, 1.25	93.59	15.59	0.00
	Severe Sepsis	152	0.83	0.22, 1.44	99.58	236.31	0.00
	Septic Shock	77	0.86	0.64, 1.09	77.66	4.48	0.03
	Survivor	430	1.12	0.92, 1.32	95.35	21.52	0.00
	Non-Survivor	172	0.83	0.76, 0.91	84.73	6.55	0.00
	Overall	923	0.95	0.88, 1.02	99.38	160.49	0.00
T4 (nmol/L)	Sepsis	39	81.10	79.48, 82.72	N/A	N/A	N/A
	Severe Sepsis	137	72.10	71.66, 72.54	0.00	1.00	0.75
	Septic Shock	61	65.60	64.63, 66.57	N/A	N/A	N/A
	Survivor	351	71.02	66.05, 75.99	88.88	8.99	0.00
	Non-Survivor	148	59.48	57.92, 61.04	0.00	1.00	0.47
	Overall	736	67.88	64.69, 71.06	98.72	78.41	0.00
TSH (mIU/mL)	Sepsis	75	2.05	1.56, 2.54	97.30	37.03	0.00
	Severe Sepsis	159	2.07	1.08, 3.06	99.00	100.25	0.00
	Septic Shock	110	2.08	1.54, 2.61	98.20	55.60	0.00
	Survivor	392	1.43	0.57, 2.28	98.36	60.93	0.00
	Non-Survivor	187	2.44	0.55, 4.33	98.77	81.45	0.00
	Overall	923	1.95	1.68, 2.22	98.34	60.07	0.00
fT3 (pmol/L)	Sepsis	36	3.68	3.08, 4.28	N/A	N/A	N/A
	Severe Sepsis	28	1.92	0.57, 3.27	99.18	122.46	0.00
	Septic Shock	49	2.78	1.11, 4.45	99.44	178.94	0.00
	Survivor	189	2.82	0.71, 4.93	99.68	311.41	0.00
	Non-Survivor	141	2.25	1.83, 2.66	85.63	6.96	0.00
	Overall	443	2.59	1.96, 3.22	99.42	131.45	0.00
fT4 (pmol/L)	Sepsis	36	1.30	1.04, 1.56	N/A	N/A	N/A
	Severe Sepsis	22	1.00	0.87, 1.13	N/A	N/A	N/A
	Septic Shock	49	9.26	0.98, 17.53	99.75	399.73	0.00
	Survivor	268	10.07	1.17, 18.97	99.89	887.12	0.00
	Non-Survivor	165	9.19	1.56, 16.81	99.45	181.96	0.00
	Overall	540	7.93	6.79, 9.06	99.71	343.51	0.00
rT3 (nmol/L)	Sepsis	N/A	N/A	N/A	N/A	N/A	N/A
	Severe Sepsis	6	0.36	0.32, 0.40	N/A	N/A	N/A
	Septic Shock	13	0.29	0.24, 0.34	N/A	N/A	N/A
	Survivor	148	0.65	0.13, 1.16	89.20	9.26	0.00
	Non-Survivor	102	1.11	-0.16, 2.39	94.00	16.66	0.00
	Overall	269	0.63	0.44, 0.82	95.03	20.10	0.00

N/A = not available

found in T3, T4, and fT3 ( $g$  [95% CI] = 1.09 [0.93-1.25]; 81.10 [79.48-82.72]; 3.68 [3.08-4.28]), compared to patients with severe sepsis and septic shock. However, in severe septic patients, rT3 had the highest effect size ( $g$  = 0.36; 95% CI = 0.32-0.40), while T3, fT3, and fT4 ( $g$  [95% CI] = 0.83 [0.22-1.44]; 1.92 [0.57-3.27]; 1.00

[0.87-1.13], respectively) had the lowest effect size, compared to septic and septic shock patients.

Conversely, in patients with septic shock, the highest effect size was found in TSH ( $g$  = 2.08; 95% CI = 1.54-2.61) and fT4 ( $g$  = 9.26; 95% CI = 0.98-17.53). The lowest effect size was in T4 ( $g$  = 65.60; 95% CI = 64.63-66.57) and rT3 ( $g$  = 0.29; 95% CI = 0.24-0.34). The



effect size of thyroid function parameters between survivors and non-survivors was also assessed. Survivor groups had a lower effect size in TSH and rT3 ( $g$  [95% CI] = 1.43 [0.57-2.28]; 0.65 [0.13-1.16], respectively). While the non-survivor group had a lower effect size for T3 ( $g = 0.83$ ; 95% CI = 0.76-0.91), T4 ( $g = 59.48$ ; 95% CI = 57.92-61.04), fT3 ( $g = 2.25$ ; 95% CI = 1.83-2.66), and fT4 ( $g = 9.19$ ; 95% CI = 1.56-16.81). Tests of group differences among sepsis, severe sepsis, septic shock, survivors, and non-survivors were statistically significant in T3, T4, fT3, and fT4 ( $p = 0.00$ ), but not in TSH and rT3 ( $p = 0.72$  and  $0.06$ , respectively). With two exceptions, heterogeneity statistics were significant in all patient groups, as well as in the overall analysis, with  $p < 0.05$  and  $I^2$  ranging from 77.66% to 99.89%. These exceptions were T4 of severe septic patients ( $p = 0.75$ ) and non-survivors ( $p = 0.47$ ). The thorough pooled analysis is listed in supplementary material as Figure S1 to Figure S7.

## 4. Discussion

Over the years, the importance of TFT has shifted from identifying thyroid dysfunction to utilizing it to interpret the severity of critical illness.<sup>19</sup> Current pooled results in this study demonstrated a low level of T<sub>3</sub> and a normal level of TSH in septic patients. Both are classic forms of NTIS or low T<sub>3</sub> syndrome (low T<sub>3</sub> with low or normal TSH and high rT<sub>3</sub>).<sup>20</sup> The previous systematic review and meta-analysis reported that decreased serum T<sub>3</sub> or T<sub>4</sub> levels are associated with adult septic patients' mortality.<sup>8</sup> In this meta-analysis, we will further explore NTIS's possibility as a prognostic factor in the various severity stages of sepsis, that is to say sepsis, severe sepsis, and septic shock.

NTIS is theorized as an adaptive and beneficial response in patients under severe acute illness. The syndrome occurs in response to the body's attempts to reduce energy expenditure to limit catabolism by lowering T<sub>3</sub> plasma level and converting it to its inactive form (rT<sub>3</sub>).<sup>21</sup> On the contrary, evidence has shown T<sub>3</sub> specific receptors tend to be higher in chronic disease patients than ICU patients; hence it seems that an adaptive state is never adequately achieved.<sup>17</sup> Therefore NTIS could be one part of organ-related failure and hypothalamic-pituitary-thyroid axis alteration in sepsis.<sup>13, 22</sup>

In this study, we found that other thyroid hormones were in the normal range and rarely changed. We also discovered that studies discussing thyroid hormones often lack adequate numbers. An important finding in our study was a low-free T<sub>4</sub> (fT<sub>4</sub>) in septic patients. fT<sub>4</sub> is known to recuperate along with the process of the patient's recovery.<sup>23</sup> This highlights the importance of fT<sub>4</sub>, where if its low persistence could indicate that there were no signs of recovery and sepsis would progress further, taking into account that reduced T<sub>3</sub> or fT<sub>4</sub> is a

dynamic process, and the levels may change over time. The prognostic interpretation needs to be carefully considered given the possibility of delay in the ICU admission.<sup>6</sup> Decreased T<sub>3</sub> in the acute critical phase may indicate the severity of illness, whereas a chronic phase may portray the patient's recovery.<sup>24</sup>

With the evidence of thyroid hormones and their clinical correlation, NTIS in septic patients can also be explained by two different time courses. During acute critical illness, there is fewer thyroid binding globulin in the serum.<sup>24, 25</sup> The changes in the peripheral conversion of T<sub>4</sub> to T<sub>3</sub> during acute phase is more noticeable due to a decline in the number of active type-1 deiodinase (D1) and increases type-3 deiodinase (D3) activity.<sup>18</sup> These changes may explain our findings of low T<sub>3</sub> and elevated rT<sub>3</sub> in non-survivor groups. Subsequently, type-2 deiodinases (D2) which are essential for the local conversion of T<sub>4</sub> to T<sub>3</sub> are altered during the prolonged phase of illness. The expression of deiodinases (*DIO2* mRNA), which is essential for the local conversion of T<sub>4</sub> to T<sub>3</sub> in human muscles, is also decreased during bacterial sepsis.<sup>26</sup> D2 is also expressed in tanycyte, a unique glial cell that lies in the mediobasal hypothalamus. It is hypothesized that when tanycyte D2 increases in septic patients, conversion from T<sub>3</sub> to T<sub>4</sub> will rise.<sup>1</sup>

Another theory suggested that when the activity of the I 5'-deiodinase enzyme is diminished, possibly due to interleukin (IL-6) and C-reactive protein (CRP) produced in the course of sepsis,<sup>6, 7, 12</sup> it could decrease the production of T<sub>3</sub>.<sup>12</sup> IL-6, together with tumor necrosis factor alpha (TNF- $\alpha$ ), interferon (IFN- $\gamma$ ), and other stress factors may also suppress the activity of TSH, impairing its surge.<sup>1</sup> Despite that, TSH levels were normal in this study. This review also discovered that T<sub>3</sub> levels in septic patients were the highest among severe septic and septic shock patients, which can also be observed in a study by Meyer et al.<sup>6</sup> It could be due to sepsis being less profound compared to severe sepsis and septic shock. Both in acute and prolonged phases, the pulsatility of the normal TSH surge pattern is altered, which ultimately results in an overall low-level thyroid hormone.<sup>21</sup>

There are other hypotheses though that state that NTIS in septic shock is caused by deiodinase impairment. A study regarding deiodinase activity in septic shock patients demonstrated a significant increase of skeletal muscle deiodinase-3 activity compared to control ( $p < 0.01$ ).<sup>18</sup> A molecular analysis research in NTIS patients discovered a selective thyroid hormone transporter called Monocarboxylate Transporter 8 (MCT8). MCT8 is found to be significantly under-expressed in the adipose tissue. A study in lipopolysaccharides-infused septic shock pig models also showed increased

deiodinase-3 and decreased MCT8 expression along with increased NF- $\kappa$ B binding activity.<sup>27</sup> Therefore, a low number of thyroid hormone transporters besides thyroid binding protein may also contribute to NTIS development.<sup>24</sup>

After comparison between sepsis with severe sepsis, rT<sub>3</sub> levels seemed to be the lowest. This phenomenon is explained by the low level of T<sub>4</sub>, thus reducing the final amount of converted rT<sub>3</sub>.<sup>27</sup> In due course, T<sub>4</sub> levels tend to decrease as the critical state progresses. This is presented in our study by the low T<sub>4</sub> level in the non-survivor group. Besides, pooled data regarding rT<sub>3</sub> and T<sub>4</sub> is derived from a single limited study, warranting a high chance of bias. This study also found that the incidence of NTIS in septic shock is high. A study of 27 septic shock patients demonstrated 26 patients (96.3%) had NTIS, and 15 were persistent at 28 days.<sup>13</sup> Similarly, another study of 14 septic shock patients showed that nine patients had a classic NTIS form, and three patients had low T<sub>3</sub> levels.<sup>17</sup>

Ultimately, TFT should be interpreted attentively according to each patient's clinical course. The onset, severity, and duration of the critical illness can affect TFT outcomes.<sup>28</sup> In this meta-analysis, we analyzed all thyroid hormones during admission or early critical state. Furthermore, there is a chance of variability in the reference range for fT<sub>4</sub> and fT<sub>3</sub> estimates, so it is recommended to check the method-specific normal values before interpreting the results thoroughly.

Researchers have tried replacement therapy in a setting of critical care facilities to treat NTIS in hopes of a better recovery.<sup>2, 21</sup> A study by Todd suggested that levothyroxine (T<sub>4</sub>) administration is fruitless because eventually, it will be converted to rT<sub>3</sub>.<sup>12</sup> Another study also reported that selenium, as an essential mineral that plays a crucial role in thyroid metabolism, could improve morbidity. Nevertheless, there was no direct effect on free and total thyroid hormones.<sup>29</sup> Hence, this thyroid hormone replacement strategy remains unclear and needs to be further investigated by large-scale randomized clinical trials to understand the benefits for critically ill patients with NTIS.<sup>2</sup>

## 5. Limitations

There were several limitations in the current meta-analysis that need to be addressed. First, the significant heterogeneity might be attributed to differing definitions of NTIS. There should be a consensus for the definition for NTIS depending on its origin.<sup>30</sup> Second, the included studies in this review had differences in their reference range for thyroid hormones which may affect how well differences can be interpreted across studies. Physicians should remain mindful of their normal values.

## 6. Conclusion

In summary, we can conclude that thyroid hormone levels differ according to the severity of sepsis. non-thyroidal illness syndrome is a prognostic factor in septic patients, and it is associated with an increased risk of mortality. Based on these findings, the measurement of serum T<sub>3</sub> in adult septic patients could be beneficial for predicting the severity of sepsis and can potentially help prognosticate patients.

## 7. Conflict of interests

None declared by the authors.

## 8. Author's Contribution

RW/MM/SA: Conceptualization, design, supervision, analysis and/or interpretation, writing, critical review.

NAK/APW/DH/NY/KL/YPK: Materials, data collection and/or processing, analysis and/or interpretation, literature review, writing.

## 9. References

1. Mokart D, Merlin M, Sannini A, Brun JP, Delpero JR, Houvenaeghel G, et al. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. *Br J Anaesth.* 2005;94:767-73. [PubMed] DOI: [10.1093/bja/aei143](https://doi.org/10.1093/bja/aei143)
2. van Boekel RLM, Warlé MC, Nielen RGC, Vissers KCP, van der Sande R, Bronkhorst EM, et al. Relationship between postoperative pain and overall 30-day complications in a broad surgical population: an observational study. *Ann Surg.* 2019;269:856-65. [PubMed] DOI: [10.1097/SLA.0000000000002583](https://doi.org/10.1097/SLA.0000000000002583)
3. Priebe H-J. Pharmacological modification of the perioperative stress response in noncardiac surgery. *Best Pract Res Clin Anaesthesiol.* 2016;30:171-89. [PubMed] DOI: [10.1016/j.bpa.2016.03.001](https://doi.org/10.1016/j.bpa.2016.03.001)
4. Li Y, Wang B, Zhang LL, He SF, Hu XW, Wong GT, et al. Dexmedetomidine combined with general anesthesia provides similar intraoperative stress response reduction when compared with a combined general and epidural anesthetic technique. *Anesth Analg.* 2016;122:1202-10. [PubMed] DOI: [10.1213/ANE.0000000000001165](https://doi.org/10.1213/ANE.0000000000001165)
5. Wang C, Dato T, Zhao H, Wu L, Date A, Jiang C, et al. Midazolam and dexmedetomidine affect neuroglioma and lung carcinoma cell biology in vitro and in vivo. *Anesthesiology.* 2018;129:1000-14. [PubMed] DOI: [10.1097/ALN.0000000000002401](https://doi.org/10.1097/ALN.0000000000002401)
6. Koppert W, Weigand M, Neumann F, Sittl R, Schuetzler J, Schmelz M, et al. Perioperative intravenous lidocaine has preventive effects on postoperative pain and morphine consumption after major abdominal surgery. *Anesth Analg.* 2004;98:1050-5. [PubMed] DOI: [10.1213/01.ANE.0000104582.71710.EE](https://doi.org/10.1213/01.ANE.0000104582.71710.EE)

7. Harvey KP, Adair JD, Isho M, Robinson R. Can intravenous lidocaine decrease postsurgical ileus and shorten hospital stay in elective bowel surgery? A pilot study and literature review. *Am J Surg.* 2009;198:231-6. [PubMed] DOI: [10.1016/j.amjsurg.2008.10.015](https://doi.org/10.1016/j.amjsurg.2008.10.015)
8. Kuo CP, Jao SW, Chen KM, Wong CS, Yeh CC, Sheen MJ, et al. Comparison of the effects of thoracic epidural analgesia and i.v. infusion with lidocaine on cytokine response, postoperative pain and bowel function in patients undergoing colonic surgery. *Br J Anaesth.* 2006;97:640-6. [PubMed] DOI: [10.1093/bja/ael217](https://doi.org/10.1093/bja/ael217)
9. Faul F, Erdfelder E, Lang AG, Buchner A. G\*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods.* 2007;39:175-91. [PubMed] DOI: [10.3758/bf03193146](https://doi.org/10.3758/bf03193146)
10. Zhang JM, An J. Cytokines, inflammation, and pain. *Int Anesthesiol Clin.* 2007;45:27-37. [PubMed] DOI: [10.1097/AIA.0b013e318034194e](https://doi.org/10.1097/AIA.0b013e318034194e)
11. Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. *Adv Exp Med Biol.* 2003;521:1-21. [PubMed]
12. Yang XH, Bai Q, Lv MM, Fu HG, Dong TL, Zhou Z. Effect of dexmedetomidine on immune function of patients undergoing radical mastectomy: a double blind and placebo control study. *Eur Rev Med Pharmacol Sci.* 2017;21:1112-6. [PubMed]
13. Dong W, Chen MH, Yang YH, Zhang X, Huang MJ, Yang XJ, et al. The effect of dexmedetomidine on expressions of inflammatory factors in patients with radical resection of gastric cancer. *Eur Rev Med Pharmacol Sci.* 2017;21:3510-5. [PubMed]
14. Ma J, Chen Q, Li J, Zhao H, Mi E, Chen Y, et al. Dexmedetomidine-mediated prevention of renal ischemia-reperfusion injury depends in part on cholinergic anti-inflammatory mechanisms. *Anesth Analg.* 2020;130:1054-62. [PubMed] DOI: [10.1213/ANE.0000000000003820](https://doi.org/10.1213/ANE.0000000000003820)
15. Wang XW, Cao JB, Lv BS, Mi WD, Wang ZQ, Zhang C, et al. Effect of perioperative dexmedetomidine on the endocrine modulators of stress response: a meta-analysis. *Clin Exp Pharmacol Physiol.* 2015;42:828-36. [PubMed] DOI: [10.1111/1440-1681.12431](https://doi.org/10.1111/1440-1681.12431)
16. Draghiciu O, Nijman HW, Daemen T. From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. *Clin Dev Immunol.* 2011;2011:439053. [PubMed] DOI: [10.1155/2011/439053](https://doi.org/10.1155/2011/439053)
17. Singh S, Singh A. Dexmedetomidine induced catecholamine suppression in pheochromocytoma. *J Nat Sci Biol Med.* 2014;5:182-3. [PubMed] DOI: [10.4103/0976-9668.127323](https://doi.org/10.4103/0976-9668.127323)
18. Yardeni IZ, Beilin B, Mayburd E, Levinson Y, Bessler H. The effect of perioperative intravenous lidocaine on postoperative pain and immune function. *Anesth Analg.* 2009;109:1464-9. [PubMed] DOI: [10.1213/ANE.0b013e3181bab1bd](https://doi.org/10.1213/ANE.0b013e3181bab1bd)
19. Wu CT, Borel CO, Lee MS, Yu JC, Liou HS, Yi HD, et al. The interaction effect of perioperative cotreatment with dextromethorphan and intravenous lidocaine on pain relief and recovery of bowel function after laparoscopic cholecystectomy. *Anesth Analg.* 2005;100:448-53. [PubMed] DOI: [10.1213/01.ANE.0000142551.92340.CC](https://doi.org/10.1213/01.ANE.0000142551.92340.CC)
20. Kaba A, Laurent SR, Detroz BJ, Sessler DI, Durieux ME, Lamy ML, et al. Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy. *Anesthesiology.* 2007;106:11-8. [PubMed] DOI: [10.1097/00000542-200701000-00007](https://doi.org/10.1097/00000542-200701000-00007)
21. Sridhar P, Sistla SC, Ali SM, Karthikeyan VS, Badhe AS, Ananthanarayanan PH. Effect of intravenous lignocaine on perioperative stress response and post-surgical ileus in elective open abdominal surgeries: a double-blind randomized controlled trial. *ANZ J Surg.* 2015;85:425-9. [PubMed] DOI: [10.1111/ans.12783](https://doi.org/10.1111/ans.12783)
22. Wuethrich PY, Romero J, Burkhard FC, Curatolo M. No benefit from perioperative intravenous lidocaine in laparoscopic renal surgery: a randomised, placebo-controlled study. *Eur J Anaesthesiol.* 2012;29:537-43. [PubMed] DOI: [10.1097/EJA.0b013e328356bad6](https://doi.org/10.1097/EJA.0b013e328356bad6)
23. Hofer S, Steppan J, Wagner T, Funke B, Lichtenstern C, Martin E, et al. Central sympatholytics prolong survival in experimental sepsis. *Crit Care.* 2009;13:R11. [PubMed] DOI: [10.1186/cc7709](https://doi.org/10.1186/cc7709)
24. Bagry H, de la Cuadra Fontaine JC, Asenjo JF, Bracco D, Carli F. Effect of a continuous peripheral nerve block on the inflammatory response in knee arthroplasty. *Reg Anesth Pain Med.* 2008;33:17-23. [PubMed] DOI: [10.1016/j.rapm.2007.06.398](https://doi.org/10.1016/j.rapm.2007.06.398)
25. Groudine SB, Fisher HA, Kaufman RP, Jr., Patel MK, Wilkins LJ, Mehta SA, et al. Intravenous lidocaine speeds the return of bowel function, decreases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy. *Anesth Analg.* 1998;86:235-9. [PubMed] DOI: [10.1097/00000539-199802000-00003](https://doi.org/10.1097/00000539-199802000-00003)
26. Bisgaard T, Klarskov B, Kehlet H, Rosenberg J. Preoperative dexamethasone improves surgical outcome after laparoscopic cholecystectomy: a randomized double-blind placebo-controlled trial. *Ann Surg.* 2003;238:651-60. [PubMed] DOI: [10.1097/01.sla.0000094390.82352.cb](https://doi.org/10.1097/01.sla.0000094390.82352.cb)
27. Castro I, Quisenberry L, Calvo R, Obregon M, Lado-Abeal J. Septic shock non-thyroidal illness syndrome causes hypothyroidism and conditions for reduced sensitivity to thyroid hormone. *J Mol Endocrinol.* 2013;50:255-266. [PubMed] DOI: [10.1530/JME-12-0188](https://doi.org/10.1530/JME-12-0188)
28. Soh S, Aw T. Laboratory testing in thyroid conditions - pitfalls and clinical utility. *Ann Lab Med.* 2019;39:3-14. [PubMed] DOI: [10.3343/alm.2019.39.1.3](https://doi.org/10.3343/alm.2019.39.1.3)
29. Angstwurm M, Schopohl J, Gaertner R. Selenium substitution has no direct effect on thyroid hormone metabolism in critically ill patients. *Eur J Endocrinol.* 2004;151:47-54. [PubMed] DOI: [10.1530/eje.0.1510047](https://doi.org/10.1530/eje.0.1510047)
30. Moura Neto A, Zantut-Wittmann D. Abnormalities of Thyroid Hormone Metabolism during Systemic Illness: The Low T3 Syndrome in Different Clinical Settings. *Int J Endocrinol.* 2016;2016:1-9. [PubMed] DOI: [10.1155/2016/2157583](https://doi.org/10.1155/2016/2157583)